Liquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients using it and to patients with PAH, Liquidia Corporation can continue generating revenue. YUTREPIA is already generating cash. Paid PAH starts will show how much of the lost PH-ILD growth LQDA can replace.

